Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Universal school-based MDD screening increases identification of adolescents with MDD symptoms and initiation of treatment.
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Differences in sleep patterns, which can be objectively measured with wrist-worn accelerometers, are the norm among patients with lifetime psychiatric conditions.
Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
The FDA has cleared Nexstim's NBT system for the treatment of major depressive disorder.
For patients with major depressive disorde, relapse is associated with brain cortical changes over two years.
Mirtazapine is a central alpha-2 antagonist currently FDA-approved for the treatment of major depressive disorder.
Serotonergic antidepressants are effective for sleep disturbances in perimenopausal and postmenopausal women even without major depressive disorder.